• Something wrong with this record ?

Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma

L. Haertle, S. Barrio, U. Munawar, S. Han, X. Zhou, M. Simicek, C. Vogt, M. Truger, RA. Fernandez, M. Steinhardt, J. Weingart, R. Snaurova, S. Nerreter, E. Teufel, A. Garitano-Trojaola, M. Da Viá, Y. Ruiz-Heredia, A. Rosenwald, N. Bolli, R....

. 2023 ; 29 (1) : 279-288. [pub] 2023Jan04

Language English Country United States

Document type Meta-Analysis, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23004657

PURPOSE: Proteasome inhibitors (PI) are the backbone of various treatment regimens in multiple myeloma. We recently described the first in-patient point mutations affecting the 20S subunit PSMB5 underlying PI resistance. Notably, in vivo, the incidence of mutations in PSMB5 and other proteasome encoding genes is too low to explain the development of resistance in most of the affected patients. Thus, additional genetic and epigenetic alterations need to be explored. EXPERIMENTAL DESIGN: We performed DNA methylation profiling by Deep Bisulfite Sequencing in PSMB5, PSMC2, PSMC5, PSMC6, PSMD1, and PSMD5, a subset of proteasome subunits that have hitherto been associated with PI resistance, recruited from our own previous research, the literature, or a meta-analysis on the frequency of somatic mutations. Methylation was followed up on gene expression level and by dual-luciferase reporter assay. The KMS11 cell line served as a model to functionally test the impact of demethylating agents. RESULTS: We identified PSMD5 promoter hypermethylation and subsequent epigenetic gene silencing in 24% of PI refractory patients. Hypermethylation correlated with decreased expression and the regulatory impact of this region was functionally confirmed. In contrast, patients with newly diagnosed multiple myeloma, along with peripheral blood mononuclear cells and CD138+ plasma cells from healthy donors, generally show unmethylated profiles. CONCLUSIONS: Under the selective pressure of PI treatment, multiple myeloma cells acquire methylation of the PSMD5 promoter silencing the PSMD5 gene expression. PSMD5 acts as a key orchestrator of proteasome assembly and its downregulation was described to increase the cell's proteolytic capacity. PSMD5 hypermethylation, therefore, represents a novel mechanism of PI tolerance in multiple myeloma.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004657
003      
CZ-PrNML
005      
20230425171639.0
007      
ta
008      
230418s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1158/1078-0432.CCR-22-1161 $2 doi
035    __
$a (PubMed)36282272
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Haertle, Larissa $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany $u Department of Hematology, Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center, Complutense University Madrid, Madrid, Spain $1 https://orcid.org/0000000239279163
245    10
$a Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma / $c L. Haertle, S. Barrio, U. Munawar, S. Han, X. Zhou, M. Simicek, C. Vogt, M. Truger, RA. Fernandez, M. Steinhardt, J. Weingart, R. Snaurova, S. Nerreter, E. Teufel, A. Garitano-Trojaola, M. Da Viá, Y. Ruiz-Heredia, A. Rosenwald, N. Bolli, R. Hajek, P. Raab, MS. Raab, N. Weinhold, C. Haferlach, T. Haaf, J. Martinez-Lopez, H. Einsele, L. Rasche, KM. Kortüm
520    9_
$a PURPOSE: Proteasome inhibitors (PI) are the backbone of various treatment regimens in multiple myeloma. We recently described the first in-patient point mutations affecting the 20S subunit PSMB5 underlying PI resistance. Notably, in vivo, the incidence of mutations in PSMB5 and other proteasome encoding genes is too low to explain the development of resistance in most of the affected patients. Thus, additional genetic and epigenetic alterations need to be explored. EXPERIMENTAL DESIGN: We performed DNA methylation profiling by Deep Bisulfite Sequencing in PSMB5, PSMC2, PSMC5, PSMC6, PSMD1, and PSMD5, a subset of proteasome subunits that have hitherto been associated with PI resistance, recruited from our own previous research, the literature, or a meta-analysis on the frequency of somatic mutations. Methylation was followed up on gene expression level and by dual-luciferase reporter assay. The KMS11 cell line served as a model to functionally test the impact of demethylating agents. RESULTS: We identified PSMD5 promoter hypermethylation and subsequent epigenetic gene silencing in 24% of PI refractory patients. Hypermethylation correlated with decreased expression and the regulatory impact of this region was functionally confirmed. In contrast, patients with newly diagnosed multiple myeloma, along with peripheral blood mononuclear cells and CD138+ plasma cells from healthy donors, generally show unmethylated profiles. CONCLUSIONS: Under the selective pressure of PI treatment, multiple myeloma cells acquire methylation of the PSMD5 promoter silencing the PSMD5 gene expression. PSMD5 acts as a key orchestrator of proteasome assembly and its downregulation was described to increase the cell's proteolytic capacity. PSMD5 hypermethylation, therefore, represents a novel mechanism of PI tolerance in multiple myeloma.
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $x farmakoterapie $x genetika $x metabolismus $7 D009101
650    _2
$a bortezomib $7 D000069286
650    _2
$a inhibitory proteasomu $x farmakologie $7 D061988
650    _2
$a proteasomový endopeptidasový komplex $x genetika $x metabolismus $7 D046988
650    _2
$a leukocyty mononukleární $x metabolismus $7 D007963
650    _2
$a chemorezistence $x genetika $7 D019008
650    _2
$a nukleotidy $7 D009711
650    _2
$a nádorové buněčné linie $7 D045744
655    _2
$a metaanalýza $7 D017418
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Barrio, Santiago $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany $u Department of Hematology, Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center, Complutense University Madrid, Madrid, Spain $u Altum Sequencing Co., Madrid, Spain $1 https://orcid.org/0000000307933535
700    1_
$a Munawar, Umair $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany $1 https://orcid.org/0000000197109923
700    1_
$a Han, Seungbin $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany $1 https://orcid.org/0000000311173102
700    1_
$a Zhou, Xiang $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany $1 https://orcid.org/0000000157727700
700    1_
$a Simicek, Michal $u Haematology, Ostrava University Hospital, Ostrava, Czech Republic $u Faculty of Medicine, Ostrava University, Ostrava, Czech Republic $1 https://orcid.org/0000000323882723 $7 xx0247832
700    1_
$a Vogt, Cornelia $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany $1 https://orcid.org/0000000277494227
700    1_
$a Truger, Marietta $u MLL Munich Leukemia Laboratory, Munich, Germany $1 https://orcid.org/0000000222860656
700    1_
$a Fernandez, Rafael Alonso $u Department of Hematology, Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center, Complutense University Madrid, Madrid, Spain $1 https://orcid.org/000000033774118X
700    1_
$a Steinhardt, Maximilian $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany $1 https://orcid.org/0000000336449187
700    1_
$a Weingart, Julia $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany $1 https://orcid.org/0000000193026047
700    1_
$a Snaurova, Renata $u Haematology, Ostrava University Hospital, Ostrava, Czech Republic $u Faculty of Medicine, Ostrava University, Ostrava, Czech Republic $1 https://orcid.org/000000026979844X
700    1_
$a Nerreter, Silvia $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany $1 https://orcid.org/0000000152521519
700    1_
$a Teufel, Eva $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany $1 https://orcid.org/0000000231600434
700    1_
$a Garitano-Trojaola, Andoni $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany $1 https://orcid.org/0000000167347779
700    1_
$a Da Viá, Matteo $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany $u Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy $u Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy $1 https://orcid.org/0000000253966584
700    1_
$a Ruiz-Heredia, Yanira $u Department of Hematology, Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center, Complutense University Madrid, Madrid, Spain $u Altum Sequencing Co., Madrid, Spain $1 https://orcid.org/0000000298952100
700    1_
$a Rosenwald, Andreas $u Institute of Pathology, University of Würzburg, Würzburg, Germany $1 https://orcid.org/0000000172828374
700    1_
$a Bolli, Niccolò $u Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy $u Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy $1 https://orcid.org/0000000210185139
700    1_
$a Hajek, Roman $u Haematology, Ostrava University Hospital, Ostrava, Czech Republic $u Faculty of Medicine, Ostrava University, Ostrava, Czech Republic $1 https://orcid.org/0000000169556267 $7 nlk20000083645
700    1_
$a Raab, Peter $u Department of Orthopaedic Surgery, König Ludwig Haus, University of Würzburg, Würzburg, Germany $1 https://orcid.org/0000000160635831
700    1_
$a Raab, Marc S $u Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany $u Clinical Cooperation Unit Molecular Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, and German Cancer Research Center (DKFZ), Heidelberg, Germany $1 https://orcid.org/0000000341816922
700    1_
$a Weinhold, Niels $u Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany $1 https://orcid.org/0000000254643234
700    1_
$a Haferlach, Claudia $u MLL Munich Leukemia Laboratory, Munich, Germany $1 https://orcid.org/0000000263335049
700    1_
$a Haaf, Thomas $u Institute of Human Genetics, Julius Maximilians University Würzburg, Würzburg, Germany $1 https://orcid.org/0000000207370763
700    1_
$a Martinez-Lopez, Joaquin $u Department of Hematology, Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center, Complutense University Madrid, Madrid, Spain $u Altum Sequencing Co., Madrid, Spain $1 https://orcid.org/0000000179080063
700    1_
$a Einsele, Hermann $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany $1 https://orcid.org/0000000276800819
700    1_
$a Rasche, Leo $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany $1 https://orcid.org/0000000295369649
700    1_
$a Kortüm, K Martin $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany $1 https://orcid.org/0000000270110286
773    0_
$w MED00001121 $t Clinical cancer research : an official journal of the American Association for Cancer Research $x 1557-3265 $g Roč. 29, č. 1 (2023), s. 279-288
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36282272 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171636 $b ABA008
999    __
$a ok $b bmc $g 1925006 $s 1190866
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 29 $c 1 $d 279-288 $e 2023Jan04 $i 1557-3265 $m Clinical cancer research $n Clin Cancer Res $x MED00001121
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Archiving options